Medolife Rx Completes Initial Meeting with Bioethics

Medolife Rx Completes Initial Meeting with Bioethics Committee, Preparing for Commencement of Phase II Clinical Trial on Lead Drug Candidate
May 20, 2021 08:00 ET
| Source:
Quanta, Inc.
Quanta, Inc.
BURBANK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it completed its initial meetings with CONABIOS, the medical ethics committee that oversees all clinical trial programs in the Dominican Republic (DR). The meeting outlined the next steps in its clinical program on Escozine® as a treatment for the SARS-CoV-2 (COVID-19) virus and the Company is seeking approval to commence clinical trials.

Related Keywords

United States ,Dominican Republic ,America ,Tom Nelson ,Arthur Mikaelian ,Kyle Porter ,Exchange Commission ,Medolife Rx Inc ,Ministry Of Health ,Drug Administration ,Aquanta Inc ,Investigational New Drug ,Harbor Statement ,Securities Litigation Reform Act ,Other Otc Qnta ,Aguanta ,Nc ,Clinical Trial ,Medolife Rx ,Sars Cov 2 Covid 19 ,Onabios ,ஒன்றுபட்டது மாநிலங்களில் ,டொமினிகன் குடியரசு ,அமெரிக்கா ,டோம் நெல்சன் ,கைல் போர்டர் ,பரிமாற்றம் தரகு ,அமைச்சகம் ஆஃப் ஆரோக்கியம் ,குவாண்டா இன்க் ,துறைமுகம் அறிக்கை ,பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,ந்ஸீ ,